Oncology

Review top news and interview highlights from the week ending October 18, 2024.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending October 11, 2024.

Kiromic reported that the fourth patient to have been treated in the trial showed a 5.3% reduction in tumor size with regard to baseline.

The ORR in the enhanced lymphodepletion arm was 100% in patients who had not previously received an antiBCMA therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending October 4, 2024.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

Estrella noted that the patient had been diagnosed with follicular lymphoma grade 3A with high-risk 3B symptoms.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Anixa noted that it had previously obtained clearance of a single-patient investigational new drug application to redose a patient in the trial.

The data, from the CARTITUDE-4 clinical trial, compared outcomes to patients treated with standard of care options.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

Review top news and interview highlights from the week ending September 27, 2024.

Enrollment difficulties were cited as the reason for discontinuing recruitment activities for KarMMa-9.

Notably, today, September 26, is annually observed as Mesothelioma Awareness Day by the patient and clinician communities.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Kiromic anticipates that Deltacel-01's expansion portion, which is expected to include around 9 new patients, will begin screening patients before the end of September.

Review top news and interview highlights from the week ending September 20, 2024.

The product is currently being evaluated in a phase 1/1b clinical trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

VNX-101 is intended to transduce cells of the liver, causing them to express a transgene coding for a bispecific T-cell engager.

Catch up on any of the key data updates you may have missed last month, with coverage highlights from the CGTLive™ team.

The company also discontinued its other clinical programs as well, which included small molecule and monoclonal antibody modalities.

Review top news and interview highlights from the week ending September 13, 2024.